Loading...
XSHG603811
Market cap337mUSD
Jan 03, Last price  
7.55CNY
1D
-1.18%
1Q
-0.66%
IPO
16.15%
Name

Zhejiang Cheng Yi Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603811 chart
P/E
15.17
P/S
3.68
EPS
0.50
Div Yield, %
2.99%
Shrs. gr., 5y
-0.15%
Rev. gr., 5y
4.24%
Revenues
672m
+2.54%
215,280,625255,433,213266,056,314320,232,009316,953,907321,223,084340,892,105545,765,999681,227,988758,132,059693,964,770654,972,841671,626,943
Net income
163m
+0.81%
13,350,70529,301,43836,497,63553,853,78857,705,08168,169,23869,238,44596,911,570131,391,821165,143,823170,797,181161,583,203162,896,651
CFO
195m
+17.38%
10,041,20037,958,50048,186,70084,108,70981,942,63795,079,58166,750,889134,298,067181,013,149177,805,369143,488,423165,937,267194,780,877
Dividend
Jun 11, 20240.2 CNY/sh
Earnings
May 16, 2025

Profile

Zhejiang Cheng Yi Pharmaceutical Co., Ltd. produces and sells APIs and capsules/tablets in China. The company was formerly known as Wenzhou No. 3 Pharmaceutical Factory and changed its name to Zhejiang Cheng Yi Pharmaceutical Co., Ltd. in April 2001. Zhejiang Cheng Yi Pharmaceutical Co., Ltd. was founded in 1966 and is headquartered in Wenzhou, China.
URL
http://www.chengyipharma.com/
IPO date
Mar 15, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
671,627
2.54%
654,973
-5.62%
Cost of revenue
424,805
455,228
Unusual Expense (Income)
NOPBT
246,822
199,745
NOPBT Margin
36.75%
30.50%
Operating Taxes
12,012
2,659
Tax Rate
4.87%
1.33%
NOPAT
234,810
197,086
Net income
162,897
0.81%
161,583
-5.39%
Dividends
(73,949)
(58,447)
Dividend yield
2.19%
1.79%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
126,990
91,124
Long-term debt
317,320
336,585
Deferred revenue
21,286
16,932
Other long-term liabilities
1
Net debt
(130,963)
(21,041)
Cash flow
Cash from operating activities
194,781
165,937
CAPEX
(70,854)
Cash from investing activities
(59,601)
Cash from financing activities
(55,376)
207,253
FCF
188,106
(65,629)
Balance
Cash
294,141
213,507
Long term investments
281,132
235,243
Excess cash
541,691
416,001
Stockholders' equity
1,055,381
856,185
Invested Capital
1,119,297
1,115,052
ROIC
21.02%
19.73%
ROCE
14.72%
12.90%
EV
Common stock shares outstanding
325,793
327,304
Price
10.37
3.80%
9.99
-13.81%
Market cap
3,378,477
3.32%
3,269,769
-13.81%
EV
3,251,812
3,251,775
EBITDA
324,942
262,112
EV/EBITDA
10.01
12.41
Interest
15,329
9,133
Interest/NOPBT
6.21%
4.57%